参考文献/References:
[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. DOI:10.3322/caac.21262.
[3] DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013[J]. CA Cancer J Clin, 2014, 64(1):52-62. DOI:10.3322/caac.21203.
[4] Pysz MA, Gambhir SS, Willmann JK. Molecular imaging:current status and emerging strategies[J]. Clin Radiol, 2010, 65(7):500-516. DOI:10.1016/j.crad.2010.03.011.
[5] Wang X, Feng H, Zhao S, et al. SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis:from bench to clinic[J]. Oncotarget, 2017, 8(12):20476-20495. DOI:10.18632/oncotarget.14730.
[6] Meng Q, Li Z. Molecular imaging probes for diagnosis and therapy evaluation of breast cancer[J]. Int J Biomed Imaging, 2013, 2013:230487. DOI:10.1155/2013/230487.
[7] Niu G, Chen X. Why integrin as a primary target for imaging and therapy[J]. Theranostics, 2011(1):30-47.
[8] Wang F, Li Y, Shen Y, et al. The functions and applications of RGD in tumor therapy and tissue engineering[J]. Int J Mol Sci, 2013, 14(7):13447-13462. DOI:10.3390/ijms140713447.
[9] Liu L, Song Y, Gao S, et al. 99Tcm-3PRGD2 scintimammography in palpable and nonpalpable breast lesions[J]. Mol Imaging, 2014, 13(5):1-7. DOI:10.2310/7290.2014.00010.
[10] Chen Q, Ma Q, Chen M, et al. An exploratory study on 99mTc-RGD-BBN peptide scintimammography in the assessment of breast malignant lesions compared to 99mTc-3P4-RGD2[J/OL]. PLoS One, 2015, 10(4):e0123401[2017-11-15]. http://journals.plos.org/plosone/article?id=10.1371/journal.pone. 0123401. DOI:10.1371/journal.pone.0123401.
[11] Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer:current progress, unresolved questions and future directions[J]. Angiogenesis, 2014, 17(3):471-494. DOI:10.1007/s10456-014-9420-y.
[12] Bohl CR, Harihar S, Denning WL, et al. Metastasis suppressors in breast cancers:mechanistic insights and clinical potential[J]. J Mol Med (Berl), 2014, 92(1):13-30. DOI:10.1007/s00109-013-1109-y.
[13] Brooks SA, Lomax-Browne HJ, Carter TM, et al. Molecular interactions in cancer cell metastasis[J]. Acta Histochem, 2010, 112(1):3-25. DOI:10.1016/j.acthis.2008.11.022.
[14] Haubner RH, Wester HJ, Weber WA, et al. Radiotracer-based strategies to image angiogenesis[J]. Q J Nucl Med, 2003, 47(3):189-199.
[15] 陈贵兵, 欧阳忠, 韩成坤, 等. 99Tcm-3PRGD2整合素受体显像在乳腺癌定性诊断中的价值及与钼靶检查的对比研究[J]. 国际放射医学核医学杂志, 2017, 41(1):1-7. DOI:10.3760/cma.j.issn.1673-4114.2017.01.001. Chen GB, Ouyang Z, Han CK, et al. Evaluation of 99Tcm-3PRGD2 integrin receptor imaging in qualitative diagnosis of breast cancer and its comparison with mammography[J]. Int J Radiat Med Nucl Med, 2017, 41(1):1-7.
[16] Pichler BJ, Kneilling M, Haubner R, et al. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD[J]. J Nucl Med, 2005, 46(1):184-189.
[17] McDonald DM, Choyke PL. Imaging of angiogenesis:from microscope to clinic[J]. Nat Med, 2003, 9(6):713-725. DOI:10.1038/nm0603-713.
[18] Chen G, Ouyang Z, Wang F, et al. Evaluation of Tc-99m-3PRGD2 Integrin Receptor Imaging in the Differential Diagnosis of Breast Lesions and Comparison With Mammography[J]. Cancer Invest, 2017, 35(2):108-115. DOI:10.1080/07357907.2016.1270957.
[19] Cochet A, Pigeonnat S, Khoury B, et al. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT:comparison with angiogenesis markers and prognostic factors[J]. J Nucl Med, 2012, 53(4):512-520. DOI:10.2967/jnumed.111.096834.
相似文献/References:
[1]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[2]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[3]储小飞,赵舒怡,樊赛军.肿瘤干细胞与辐射抗性的研究进展[J].国际放射医学核医学杂志,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
chu xiaofei,zhao shuyi,fan saijun..advance progress of cancer stem cells and radioresistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
[4]陈伟君,孙达.99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J].国际放射医学核医学杂志,2015,39(6):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
Chen Weijun,Sun Da.Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
[5]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[6]黄娟,颜剑豪,梁联保,等.注射钆剂后弥散加权成像对乳腺肿瘤诊断的影响[J].国际放射医学核医学杂志,2015,39(4):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
Huang Juan,Yan Jianhao,Liang Lianbao,et al.Evaluation of the diffusion-weighted imaging after contrast for the characterization of breast tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
[7]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[8]殷丽娜,张旭霞,张俊香,等.Wnt/β-catenin信号通路——乳腺癌的潜在治疗靶点[J].国际放射医学核医学杂志,2014,38(4):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
Yin Lina,Zhang Xuxia,Zhang Junxiang,et al.The Wnt/β-catenin signaling pathway-a potential therapeutic target of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
[9]刘超,邓智勇,刘鹏杰,等.89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析[J].国际放射医学核医学杂志,2014,38(5):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
Liu Chao,Deng Zhi-yong,Liu Peng-jie,et al.Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
[10]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]